Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Next-Generation Diagnostics in the Management of Metastatic Colorectal Cancer Patients
share announcement

Next-Generation Diagnostics in the Management of Metastatic Colorectal Cancer Patients

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (25 March 2023) | Viewed by 3544

Special Issue Editors

Prof. Dr. Matteo Fassan

E-Mail Website
Guest Editor
Department of Medicine (DIMED), Surgical Pathology Unit, University of Padua, Via Giustiniani, 35128 Padua, Italy
Interests: colorectal cancer; gastric cancer; dysplasia; molecular carcinogenesis; predictive biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Valentina Angerilli

E-Mail Website
Guest Editor
Department of Medicine (DIMED), University of Padua, Padua, Italy
Interests: gastrointestinal pathology; biomarkers; molecular pathology; histopathology

Special Issue Information

Dear Colleagues,

In the colorectal adenocarcinoma setting, several new predictive biomarkers have recently been introduced into pathologists’ clinical practice. This increasing complexity is determined by the application of precision oncology coupled with major technological advances. In this context, the pathologist has acquired a key role in the evaluation of the histomolecular background of the lesions. This Special Issue will focus on both the molecular characterization and innovative molecularly based targeted therapies in metastatic colorectal adenocarcinomas.

Prof. Dr. Matteo Fassan
Dr. Valentina Angerilli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colon cancer
  • diagnostics
  • predictive biomarkers
  • pathology
  • MSI
  • BRAF
  • EGFR
  • HER2

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 4220 KiB  
Review
Minimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?
by Alexandre A. Jácome and Benny Johnson
Cells 2023, 12(7), 1068; https://doi.org/10.3390/cells12071068 - 1 Apr 2023
Cited by 3 | Viewed by 3122
Abstract
Despite significant advances in the surgical and systemic therapy of colorectal cancer (CRC) in recent decades, recurrence rates remain high. Apart from microsatellite instability status, the decision to offer adjuvant chemotherapy to patients with CRC is solely based on clinicopathologic factors, which offer [...] Read more.
Despite significant advances in the surgical and systemic therapy of colorectal cancer (CRC) in recent decades, recurrence rates remain high. Apart from microsatellite instability status, the decision to offer adjuvant chemotherapy to patients with CRC is solely based on clinicopathologic factors, which offer an inaccurate risk stratification of patients who derive benefit from adjuvant therapy. Owing to the recent improvements of molecular techniques, it has been possible to detect small allelic fractions of circulating tumor DNA (ctDNA), and therefore, to identify patients with minimal residual disease (MRD) after curative-intent therapies. The incorporation of ctDNA identifying MRD in clinical practice may dramatically change the standard of care of CRC, refining the selection of patients who are candidates for escalation and de-escalation of adjuvant chemotherapy, and even for organ-preservation strategies in rectal cancer. In the present review, we describe the current standard of care and the DNA sequencing methodologies and assays, present the data from completed clinical studies and list ongoing potential landmark clinical trials whose results are eagerly awaited, as well as the impact and perspectives for the near future. The discussed data bring optimism for the future of oncologic care through the hope of refined utilization of adjuvant therapies with higher efficacy and safety for patients with both localized and advanced CRC. Full article
(This article belongs to the Special Issue Next-Generation Diagnostics in the Management of Metastatic Colorectal Cancer Patients)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop